Literature DB >> 26589910

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Caroline Ebert1, Florian Perner1, Denise Wolleschak1, Tina M Schnöder2, Thomas Fischer2, Florian H Heidel3.   

Abstract

Entities:  

Keywords:  ABCB1; ABCG2; JAK2; T-cell; ruxolitinib

Mesh：

Substances：

Year:  2015        PMID： 26589910      PMCID： PMC4815733          DOI： 10.3324/haematol.2015.136754

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors:  F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal:  Leukemia       Date:  2015-08-05       Impact factor: 11.528

2.  Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Authors:  Annkristin Heine; Peter Brossart; Dominik Wolf
Journal:  Blood       Date:  2013-11-28       Impact factor: 22.113

Review 3.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

5.  P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Authors:  S Durmus; N Xu; R W Sparidans; E Wagenaar; J H Beijnen; A H Schinkel
Journal:  Pharmacol Res       Date:  2013-07-01       Impact factor: 7.658

6.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

Review 7.  Jakpot! New small molecules in autoimmune and inflammatory diseases.

Authors:  Kamran Ghoreschi; Massimo Gadina
Journal:  Exp Dermatol       Date:  2014-01       Impact factor: 3.960

8.  Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.

Authors:  Daniel B Lipka; Marie-Christine Wagner; Marek Dziadosz; Tina Schnöder; Florian Heidel; Mirle Schemionek; Junia V Melo; Thomas Kindler; Carsten Müller-Tidow; Steffen Koschmieder; Thomas Fischer
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

9.  MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Authors:  M Agrawal; B Hanfstein; P Erben; D Wolf; T Ernst; A Fabarius; S Saussele; D Purkayastha; R C Woodman; W-K Hofmann; R Hehlmann; A Hochhaus; M C Müller
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 10.  Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

Authors:  L N Eadie; T P Hughes; D L White
Journal:  Clin Pharmacol Ther       Date:  2013-10-09       Impact factor: 6.875
View more
  1 in total

1.  ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.

Authors:  Ralfs Buks; Mégane Brusson; Sylvie Cochet; Tatiana Galochkina; Bruno Cassinat; Ivan Nemazanyy; Thierry Peyrard; Jean-Jacques Kiladjian; Alexandre G de Brevern; Slim Azouzi; Wassim El Nemer
Journal:  Int J Mol Sci       Date:  2021-03-29       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.